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than 80 percent of the predicted value). Accord-
ingly, the results of the SUPER study cannot be 
extrapolated for patients with pulmonary hyper-
tension related to lung diseases.
Drs. Hoeper and Welte are correct in their sug-
gestion that there is a linear trend in the response 
among the doses in the hemodynamic measures 
and in the percentages of patients who improved 
by at least one WHO functional class. The absence 
of a dose–response effect on the primary end 
point (exercise capacity) or on tolerability with 
the three sildenafil doses (20 mg, 40 mg, and 
80 mg three times daily) may be related to com-
plete inhibition of phosphodiesterase type 5 with 
the lowest dose. However, in the extension study, 
all patients were treated with 80 mg three times 
daily (if tolerated), and we do not have prospec-
tive information on the long-term efficacy of the 
approved dose of 20 mg three times daily. Based 
on these data, 20 mg three times daily appears 
to be a reasonable initial dose; an increase to 40 mg 
three times daily, 80 mg three times daily, or both 
may be considered in order to achieve or main-
tain favorable effects. We recognize that limited 
data are currently available regarding the optimal 
dose of sildenafil for long-term treatment and 
that the use of higher doses may be hampered by 
the restricted approval.
Nazzareno Galiè, M.D.
University of Bologna 
40138 Bologna, Italy
nazzareno.galie@unibo.it
Lewis J. Rubin, M.D.
University of California at San Diego
La Jolla, CA 92103-8372
Gérald Simonneau, M.D.
Hopital Antoine Béclère 
92140 Clamart, France
Barst RJ, Rubin LJ, Long WA, et al. A comparison of continu-
ous intravenous epoprostenol (prostacyclin) with conventional 
therapy for primary pulmonary hypertension. N Engl J Med 1996;
334:296-302.
Simonneau G, Galie N, Rubin LJ, et al. Clinical classification 
of pulmonary hypertension. J Am Coll Cardiol 2004;43:Suppl 
12:5S-12S.
1.
2.
Congenital Glutamine Deficiency 
with Glutamine Synthetase Mutations
To the Editor: Häberle et al. (Nov. 3 issue)1 state 
that “the concentration of glutamate . . . was not 
elevated in either of the two patients, but this lack 
of elevation might be due to the various other 
pathways of glutamate catabolism.” We suggest 
that low-to-deficient glutamate concentrations in 
cerebrospinal fluid indicate a chronic depletion of 
neuronal glutamate stores, since astrocytic gluta-
mine synthase is crucial for their replenishment. 
After the bioenergetic coupling of and metabolite 
trafficking between astrocytes and neurons oc-
cur,2 a complete deficiency of this enzyme should 
result in a severe depletion of neuronal glutamate 
stores in the long run and, subsequently, a drain 
of intermediates of the tricarboxylic acid cycle due 
to increased new synthesis of glutamate and in-
sufficient anaplerosis through pyruvate carboxyl-
ation in neurons.3 As a consequence, concentra-
tions of glutamate in the cerebrospinal fluid may 
decrease, as seen in both patients mentioned 
above. Neurotransmission of glutamate is impor-
tant for the developing brain, for modulating neu-
ronal migration, for growth spurts of the brain, 
and for apoptosis.4 Dysfunction of these mecha-
nisms probably induces brain damage and mal-
formations,5,6 as displayed in both patients.
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To the Editor: We read with interest the report 
by Häberle et al., which indicates that systemic 
glutamine deficiency due to a glutamine synthe-
tase gene mutation results in brain malformations 
and seizures. An additional explanation might be 
related to chronic hyperammonemia resulting 
from a deficiency of glutamine synthetase. How-
ever, levels of ammonia were not reported. Gluta-
mine synthetase not only produces glutamine 
but also detoxifies ammonia.1 In the brain, glu-
tamine synthetase fuels glutamate uptake by as-
trocytes; therefore, inhibition of glutamine syn-
thetase results in increased extracellular glutamate 
levels and excitotoxic effects, leading to seizures.2 
Hyperammonemia in the setting of liver failure 
leads to neurologic impairment. Also, infants with 
enzyme abnormalities of the urea cycle, such as 
a deficiency of ornithine carbamoyltransferase, 
who survive episodes of hyperammonemia have 
a high incidence of mental retardation and cere-
bral palsy.3 In patients with lung transplants, hy-
perammonemia resulting from hepatic glutamine 
synthetase deficiency is associated with high mor-
tality.4 The observation of increased glutamine 
synthetase protein levels in the presence of re-
duced activity supports the view that hyperam-
monemia may set up a self-perpetuating cycle 
whereby ammonia can reduce glutamine synthe-
tase activity.5 Therefore, it is possible that the 
inhibition of glutamine synthetase in the brain 
may lead to increased levels of ammonia and ex-
tracellular glutamate in the brain, partly explain-
ing the clinical observations.
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The authors reply: In their letter, Dr. Kölker 
and colleagues comment on the low glutamate 
concentrations in cerebrospinal fluid in patients 
with glutamine synthetase deficiency. The au-
thors suggest that chronic depletion of neuronal 
glutamate stores is a result of the defective gluta-
mine–glutamate cycle. This is an interesting spec-
ulation and refers to the need for the investiga-
tion of neurotransmitters in cerebrospinal fluid 
during the follow-up of patients with glutamine 
synthetase deficiency, which has not been done 
in the case of the patients described in our arti-
cle. However, the low glutamate concentrations 
in cerebrospinal fluid were established with the 
use of chromatography, which is not sufficiently 
sensitive to define glutamate concentrations ac-
curately in the very low range. Therefore, it is not 
possible to include a deficiency of glutamate in ce-
rebrospinal fluid as one of the features of gluta-
mine synthetase deficiency.
The comments of Drs. Rose and Jalan refer to 
the levels of ammonia in the patients described. 
The authors speculate that hyperammonemia was 
present as a result of the absence of detoxifica-
tion with the glutamine synthetase reaction. The 
plasma ammonia level in Patient 1 was 77 μmol 
per liter. In Patient 2, the ammonia level was 
140 μmol per liter, a finding that, in fact, led to 
further metabolic investigations, including the 
amino acid profile. During the course of the dis-
ease, however, plasma ammonia levels were nor-
mal. Thus, hyperammonemia cannot be regard-
ed as a sign of glutamine synthetase deficiency. 
It would also not explain the severe malforma-
tion of the brain and extracerebral manifestations 
— for example, cutaneous manifestations. The 
comment regarding the increased levels of extra-
cellular glutamate leading to excitotoxic effects 
is difficult to reconcile with the findings of low 
glutamate levels in the cerebrospinal fluid of these 
patients.
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